The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Matthews International's revenues will increase 11.1% and EPS will expand 7.7%.
The average estimate for revenue is $252.8 million. On the bottom line, the average EPS estimate is $0.70.
Last quarter, Matthews International reported revenue of $256.4 million. GAAP reported sales were 14% higher than the prior-year quarter's $225.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.61. GAAP EPS of $0.51 for Q2 were 5.6% lower than the prior-year quarter's $0.54 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 37.0%, 60 basis points worse than the prior-year quarter. Operating margin was 9.8%, 140 basis points worse than the prior-year quarter. Net margin was 5.5%, 130 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $991.2 million. The average EPS estimate is $2.45.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 81 members out of 81 rating the stock outperform, and members rating it underperform. Among 32 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Matthews International a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Matthews International is outperform, with an average price target of $38.67.
Looking for alternatives to Matthews International? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Matthews International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks may be down, but they're far from out.
Why Schawk, Kandi Technologies, and Five Prime Therapeutics Are Today's 3 Best Stocks
The S&P 500 surges following the Crimean vote and strong U.S. economic data while Schawk, Kandi Technologies, and Five Therapeutics all gain at least 22%!
Matthews International Beats Analyst Estimates on EPS
Just the facts, Fool.